Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.66 |
| ▸ | MMP2 | P08253 | 14/20 | 0.35 |
| ▸ | MMP3 | P08254 | 10/20 | 0.35 |
| ▸ | MMP1 | P03956 | 4/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6674349 | 1.00 | TUBB1 (0.66) | TUBB1MMP2MMP3MMP1MMP9 | |
| SCHEMBL6806405 | 0.91 | TUBB1 (0.57) | TUBB1MMP2MMP3MMP1ADAM17 | |
| Taltobulin SCHEMBL57122 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL13848320 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL13751409 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL57119 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL6670481 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL16176425 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL6799555 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 | |
| Taltobulin SCHEMBL13751415 | 0.89 | TUBB1 (0.81) | TUBB1MMP2MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | claimed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885MMP2 224/4885MMP3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.